- Results
- This Paper
Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
Weng-Foung WF Huang, Yi-Wen YW Tsai, Yu-Wen YW Wen, Fei-Yuan FY Hsiao, Ken N KN Kuo and Chia-Rung CR Tsai
crossref 17(1):57-63 1 Jan 2010
PMID 19680161
Concerns have been raised about bisphosphonate use and risk of atrial fibrillation (AF) in women with osteoporosis. This study compares the risk of AF and of flutter or acute myocardial infarction (AMI) in women with osteoporosis taking alendronate or raloxifene.
DOI: 10.1097/gme.0b013e3181b34749
Version: za2963e q8za5 q8zbb q8zc7 q8zd0 q8zed q8zf1 q8zg3
DOI: 10.1097/gme.0b013e3181b34749
Version: za2963e q8za5 q8zbb q8zc7 q8zd0 q8zed q8zf1 q8zg3